{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:51:05Z","timestamp":1790049065860,"version":"4.0.1"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T00:00:00Z","timestamp":1600300800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Obes"],"published-print":{"date-parts":[[2021,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>In high-fat diet (HFD)-induced obese male C57BL\/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure\u2013activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and influence energy homeostasis. After selecting HSG4112 as our optimized compound from this discovery method, we characterized its pharmacological effects on parameters related to obesity through in vivo metabolic and biochemical measurements, histology and gene expression analysis, and indirect calorimetry.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Through the SAR study, we identified four novel components of glabridin pertinent for its anti-obesity activity, and found that HSG4112, an optimized structural analog of glabridin, markedly supersedes glabridin in weight reduction efficacy and chemical stability. Six-week administration of HSG4112 to HFD-induced obese mice led to dose-dependent normalization of obesity-related parameters, including body weight, muscle and adipose tissue weight, adipocyte size, and serum leptin\/insulin\/glucose levels. The weight reduction induced by HSG4112 was partially mediated by decreased food intake and mainly mediated by increased energy expenditure, with no change in physical activity. Accordingly, the pattern of transcriptional changes was aligned with increased energy expenditure in the liver and muscles. Following significant body weight reduction, robust amelioration of histopathology and blood markers of fatty liver were also observed.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Our study demonstrates the key chemical components of glabridin pertinent to its weight loss effects and suggests HSG4112 as a promising novel drug candidate for the pharmacological treatment of obesity.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1038\/s41366-020-00686-1","type":"journal-article","created":{"date-parts":[[2020,9,17]],"date-time":"2020-09-17T21:31:21Z","timestamp":1600378281000},"page":"130-142","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":27,"title":["Discovery and preclinical efficacy of HSG4112, a synthetic structural analog of glabridin, for the treatment of obesity"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8850-0832","authenticated-orcid":false,"given":"Leo Sungwong","family":"Choi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In Geun","family":"Jo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ku Suk","family":"Kang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeong Ho","family":"Im","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinyoung","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin Wook","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sang-Ku","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,9,17]]},"reference":[{"key":"686_CR1","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1056\/NEJMra1514009","volume":"376","author":"SB Heymsfield","year":"2017","unstructured":"Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017;376:254\u201366.","journal-title":"N Engl J Med"},{"key":"686_CR2","unstructured":"Kumar RB, Aronne LJ. Pharmacologic treatment of obesity. Endotext. 2000."},{"key":"686_CR3","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1007\/s40265-015-0410-1","volume":"75","author":"BJ Jones","year":"2015","unstructured":"Jones BJ, Bloom SR. The new era of drug therapy for obesity: the evidence and the expectations. Drugs. 2015;75:935\u201345.","journal-title":"Drugs."},{"key":"686_CR4","doi-asserted-by":"crossref","first-page":"511","DOI":"10.3945\/an.116.014506","volume":"8","author":"E Cava","year":"2017","unstructured":"Cava E, Yeat NC, Mittendorfer B. Preserving healthy muscle during weight loss. Adv Nutr An Int Rev J. 2017;8:511\u20139.","journal-title":"Adv Nutr An Int Rev J."},{"key":"686_CR5","first-page":"E923","volume":"282","author":"SB Votruba","year":"2002","unstructured":"Votruba SB, Blanc S, Schoeller DA. Pattern and cost of weight gain in previously obese women. Am J Physiol Metab. 2002;282:E923\u201330.","journal-title":"Am J Physiol Metab."},{"key":"686_CR6","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1038\/sj.ijo.0801643","volume":"25","author":"AE Field","year":"2001","unstructured":"Field AE, Wing RR, Manson JE, Spiegelman DL, Willett WC. Relationship of a large weight loss to long-term weight change among young and middle-aged US women. Int J Obes. 2001;25:1113\u201321.","journal-title":"Int J Obes."},{"key":"686_CR7","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1016\/S0891-5849(97)00089-0","volume":"23","author":"J Vaya","year":"1997","unstructured":"Vaya J, Belinky PA, Aviram M. Antioxidant constituents from licorice roots: isolation, structure elucidation and antioxidative capacity toward LDL oxidation. Free Radic Biol Med. 1997;23:302\u201313.","journal-title":"Free Radic Biol Med."},{"key":"686_CR8","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1248\/cpb.24.752","volume":"24","author":"T Saitoh","year":"2011","unstructured":"Saitoh T, Kinoshiba T, Shibata S. New isoflavan and flavanone from licorice root. Chem Pharm Bull (Tokyo). 2011;24:752\u20135.","journal-title":"Chem Pharm Bull (Tokyo)."},{"key":"686_CR9","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1248\/bpb.27.1775","volume":"27","author":"K Nakagawa","year":"2004","unstructured":"Nakagawa K, Kishida H, Arai N, Nishiyama T, Mae T. Licorice flavonoids suppress abdominal fat accumulation and increase in blood glucose level in obese diabetic KK-Ay mice. Biol Pharm Bull. 2004;27:1775\u20138.","journal-title":"Biol Pharm Bull."},{"key":"686_CR10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.fitote.2013.07.003","volume":"90","author":"C Simmler","year":"2013","unstructured":"Simmler C, Pauli GF, Chen SN. Phytochemistry and biological properties of glabridin. Fitoterapia. 2013;90:160\u201384.","journal-title":"Fitoterapia."},{"key":"686_CR11","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1194\/jlr.M022897","volume":"53","author":"J-W Lee","year":"2012","unstructured":"Lee J-W, Choe SS, Jang H, Kim J, Jeong HW, Jo H, et al. AMPK activation with glabridin ameliorates adiposity and lipid dysregulation in obesity. J Lipid Res. 2012;53:1277\u201386.","journal-title":"J Lipid Res."},{"key":"686_CR12","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/nrm3311","volume":"13","author":"DG Hardie","year":"2012","unstructured":"Hardie DG, Ross FA, Hawley SA. AMPK: a nutrient and energy sensor that maintains energy homeostasis. Nat Rev Mol Cell Biol. 2012;13:251\u201362.","journal-title":"Nat Rev Mol Cell Biol."},{"key":"686_CR13","first-page":"1907","volume":"5","author":"M Ao","year":"2010","unstructured":"Ao M, Shi Y, Cui Y, Guo W, Wang J, Yu L. Factors influencing glabridin stability. Nat Prod Commun. 2010;5:1907\u201312.","journal-title":"Nat Prod Commun."},{"key":"686_CR14","doi-asserted-by":"crossref","first-page":"358","DOI":"10.3177\/jnsv.53.358","volume":"53","author":"C Ito","year":"2007","unstructured":"Ito C, Oi N, Hashimoto T, Nakabayashi H, Aoki F, Tominaga Y, et al. Absorption of dietary licorice isoflavan glabridin to blood circulation in rats. J Nutr Sci Vitaminol (Tokyo). 2007;53:358\u201365.","journal-title":"J Nutr Sci Vitaminol (Tokyo)."},{"key":"686_CR15","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1007\/s12272-009-1501-x","volume":"32","author":"W Jirawattanapong","year":"2009","unstructured":"Jirawattanapong W, Saifah E, Patarapanich C. Synthesis of glabridin derivatives as tyrosinase inhibitors. Arch Pharm Res. 2009;32:647\u201354.","journal-title":"Arch Pharm Res."},{"key":"686_CR16","doi-asserted-by":"crossref","first-page":"481","DOI":"10.5012\/bkcs.2007.28.3.481","volume":"28","author":"SK Yoo","year":"2007","unstructured":"Yoo SK, Nahm K. Facile and efficient synthesis of (\u00b1)-glabridin. Bull Korean Chem Soc. 2007;28:481\u20134.","journal-title":"Bull Korean Chem Soc."},{"key":"686_CR17","unstructured":"Yu S-K, Suk KK, Young KJ, Wook CJ, Ho IJ, Yoo JIG. Pyranochromenyl phenol derivative, and pharmaceutical composition for treating metabolic syndrome or inflammatory disease\u2014Patent US9783551\u2014PubChem. 2017."},{"key":"686_CR18","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","volume":"41","author":"DE Kleiner","year":"2005","unstructured":"Kleiner DE, Brunt EM, Van Natta M, Behling C, Contos MJ, Cummings OW, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313\u201321.","journal-title":"Hepatology."},{"key":"686_CR19","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/nn1731","volume":"9","author":"MS Kim","year":"2006","unstructured":"Kim MS, Pak YK, Jang PG, Namkoong C, Choi YS, Won JC, et al. Role of hypothalamic Foxo1 in the regulation of food intake and energy homeostasis. Nat Neurosci. 2006;9:901\u20136.","journal-title":"Nat Neurosci."},{"key":"686_CR20","doi-asserted-by":"crossref","unstructured":"Nie Y, Gavin T, Kuang S. Measurement of resting energy metabolism in mice using oxymax open circuit indirect calorimeter. Bio-protocol. 2015;5:e1602.","DOI":"10.21769\/BioProtoc.1602"},{"key":"686_CR21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-199600525-00003","volume":"52","author":"AJ Hutt","year":"1996","unstructured":"Hutt AJ, Tan SC. Drug chirality and its clinical significance. Drugs. 1996;52:1\u201312.","journal-title":"Drugs."},{"key":"686_CR22","doi-asserted-by":"crossref","first-page":"4466","DOI":"10.1039\/c000408c","volume":"39","author":"B Kasprzyk-Hordern","year":"2010","unstructured":"Kasprzyk-Hordern B. Pharmacologically active compounds in the environment and their chirality. Chem Soc Rev. 2010;39:4466\u2013503.","journal-title":"Chem Soc Rev."},{"key":"686_CR23","doi-asserted-by":"crossref","first-page":"549","DOI":"10.4103\/2230-8210.105571","volume":"16","author":"G Paz-Filho","year":"2012","unstructured":"Paz-Filho G, Wong M-L, Licinio J, Mastronardi C. Leptin therapy, insulin sensitivity, and glucose homeostasis. Indian J Endocrinol Metab. 2012;16:549.","journal-title":"Indian J Endocrinol Metab."},{"key":"686_CR24","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1046\/j.1365-201x.1999.00518.x","volume":"165","author":"AHR\u00c9N.","year":"1999","unstructured":"AHR\u00c9N. Plasma leptin and insulin in C57Bl\/6J mice on a high-fat diet: relation to subsequent changes in body weight. Acta Physiol Scand. 1999;165:233\u201340.","journal-title":"Acta Physiol Scand."},{"key":"686_CR25","doi-asserted-by":"crossref","unstructured":"Even PC, Nadkarni NA. Indirect calorimetry in laboratory mice and rats: principles, practical considerations, interpretation and perspectives. Am J Physiol Regul Integr Comp Physiol. 2012;303:459\u201376.","DOI":"10.1152\/ajpregu.00137.2012"},{"key":"686_CR26","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1097\/00041433-200106000-00012","volume":"12","author":"GR Hynes","year":"2001","unstructured":"Hynes GR, Jones PJH. Leptin and its role in lipid metabolism. Curr Opin Lipidol. 2001;12:321\u20137.","journal-title":"Curr Opin Lipidol."},{"key":"686_CR27","doi-asserted-by":"crossref","unstructured":"Stern JH, Rutkowski JM, Scherer PE. Adiponectin, leptin, and fatty acids in the maintenance of metabolic homeostasis through adipose tissue crosstalk. Cell Metab Rev. 2016;23:770\u201384.","DOI":"10.1016\/j.cmet.2016.04.011"},{"key":"686_CR28","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1038\/ejcn.2016.231","volume":"71","author":"MJ M\u00fcller","year":"2017","unstructured":"M\u00fcller MJ, Geisler C. From the past to future: from energy expenditure to energy intake to energy expenditure. Eur J Clin Nutr. 2017;71:358\u201364.","journal-title":"Eur J Clin Nutr."},{"key":"686_CR29","first-page":"163","volume":"65","author":"AA Zaninovich","year":"2005","unstructured":"Zaninovich AA. Role of uncoupling proteins UCP1, UCP2 and UCP3 in energy balance, type 2 diabetes and obesity. Medicina (B Aires). 2005;65:163\u20139.","journal-title":"Medicina (B Aires)."},{"key":"686_CR30","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/j.bbamcr.2010.09.019","volume":"1813","author":"RC Scarpulla","year":"2011","unstructured":"Scarpulla RC. Metabolic control of mitochondrial biogenesis through the PGC-1 family regulatory network. Biochim Biophys Acta Mol Cell Res. 2011;1813:1269\u201378.","journal-title":"Biochim Biophys Acta Mol Cell Res."},{"key":"686_CR31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1038\/nm1061","volume":"10","author":"M-S Kim","year":"2004","unstructured":"Kim M-S, Park J-Y, Namkoong C, Jang P-G, Ryu J-W, Song H-S, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med. 2004;10:727\u201333.","journal-title":"Nat Med."},{"key":"686_CR32","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1111\/liv.13301","volume":"37","author":"P Bedossa","year":"2017","unstructured":"Bedossa P. Pathology of non-alcoholic fatty liver disease. Liver Int. 2017;37:85\u20139.","journal-title":"Liver Int."},{"key":"686_CR33","doi-asserted-by":"crossref","unstructured":"Van Herck MA, Vonghia L, Francque SM. Animal models of nonalcoholic fatty liver disease\u2014a starter\u2019s guide. Nutrients. 2017;9:1072.","DOI":"10.3390\/nu9101072"},{"key":"686_CR34","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cbi.2015.03.001","volume":"231","author":"B Guo","year":"2015","unstructured":"Guo B, Fang Z, Yang L, Xiao L, Xia Y, Gonzalez FJ, et al. Tissue and species differences in the glucuronidation of glabridin with UDP-glucuronosyltransferases. Chem Biol Interact. 2015;231:90\u20137.","journal-title":"Chem Biol Interact."},{"key":"686_CR35","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.bone.2017.06.010","volume":"104","author":"JA Shepherd","year":"2017","unstructured":"Shepherd JA, Ng BK, Sommer MJ, Heymsfield SB. Body composition by DXA. Bone. 2017;104:101\u20135.","journal-title":"Bone."},{"key":"686_CR36","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1111\/j.1748-1716.2011.02354.x","volume":"204","author":"L Wang","year":"2012","unstructured":"Wang L, Sahlin K. The effect of continuous and interval exercise on PGC-1\u03b1 and PDK4 mRNA in type I and type II fibres of human skeletal muscle. Acta Physiol. 2012;204:525\u201332.","journal-title":"Acta Physiol."},{"key":"686_CR37","first-page":"41","volume":"111","author":"T Ookawara","year":"2002","unstructured":"Ookawara T, Suzuki K, Haga S, Ha S, Chung KS, Toshinai K, et al. Transcription regulation of gene expression in human skeletal muscle in response to endurance training. Res Commun Mol Pathol Pharmacol. 2002;111:41\u201354.","journal-title":"Res Commun Mol Pathol Pharmacol."},{"key":"686_CR38","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1126\/science.aab4138","volume":"351","author":"EQ Toyama","year":"2016","unstructured":"Toyama EQ, Herzig S, Courchet J, Lewis TL, Los\u00f3n OC, Hellberg K, et al. Metabolism: AMP-activated protein kinase mediates mitochondrial fission in response to energy stress. Science. 2016;351:275\u201381.","journal-title":"Science."},{"key":"686_CR39","doi-asserted-by":"crossref","unstructured":"Stienstra R, Duval C, M\u00fcller M, Kersten S. PPARs, obesity, and inflammation. PPAR Res. 2007;2007:95974.","DOI":"10.1155\/2007\/95974"},{"key":"686_CR40","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1038\/nm.3159","volume":"19","author":"M Ahmadian","year":"2013","unstructured":"Ahmadian M, Suh JM, Hah N, Liddle C, Atkins AR, Downes M, et al. Ppar\u03b3 signaling and metabolism: the good, the bad and the future. Nat Med. 2013;19:557\u201366.","journal-title":"Nat Med."},{"key":"686_CR41","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1016\/j.bmc.2009.11.027","volume":"18","author":"M Kuroda","year":"2010","unstructured":"Kuroda M, Mimaki Y, Honda S, Tanaka H, Yokota S, Mae T. Phenolics from Glycyrrhiza glabra roots and their PPAR-\u03b3 ligand-binding activity. Bioorganic Med Chem. 2010;18:962\u201370.","journal-title":"Bioorganic Med Chem."},{"key":"686_CR42","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/j.fct.2012.08.048","volume":"51","author":"J Ahn","year":"2013","unstructured":"Ahn J, Lee H, Jang J, Kim S, Ha T. Anti-obesity effects of glabridin-rich supercritical carbon dioxide extract of licorice in high-fat-fed obese mice. Food Chem Toxicol. 2013;51:439\u201345.","journal-title":"Food Chem Toxicol."},{"key":"686_CR43","doi-asserted-by":"crossref","first-page":"3679","DOI":"10.1021\/jf2046009","volume":"60","author":"D Atrahimovich","year":"2012","unstructured":"Atrahimovich D, Vaya J, Tavori H, Khatib S. Glabridin protects paraoxonase 1 from linoleic acid hydroperoxide inhibition via specific interaction: a fluorescence-quenching study. J Agric Food Chem. 2012;60:3679\u201385.","journal-title":"J Agric Food Chem."},{"key":"686_CR44","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.lfs.2007.10.019","volume":"82","author":"XQ Yu","year":"2008","unstructured":"Yu XQ, Xue CC, Zhou ZW, Li CG, Du YM, Liang J, et al. In vitro and in vivo neuroprotective effect and mechanisms of glabridin, a major active isoflavan from Glycyrrhiza glabra (licorice). Life Sci. 2008;82:68\u201378.","journal-title":"Life Sci."},{"key":"686_CR45","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1007\/s12272-015-0618-3","volume":"38","author":"HJ Jung","year":"2015","unstructured":"Jung HJ, Kwon HJ. Target deconvolution of bioactive small molecules: the heart of chemical biology and drug discovery. Arch Pharm Res. 2015;38:1627\u201341.","journal-title":"Arch Pharm Res"},{"key":"686_CR46","doi-asserted-by":"crossref","unstructured":"Friman T. Mass spectrometry-based Cellular Thermal Shift Assay (CETSA\u00ae) for target deconvolution in phenotypic drug discovery. Bioorg Med Chem. 2020;28:115174.","DOI":"10.1016\/j.bmc.2019.115174"},{"key":"686_CR47","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","volume":"149","author":"E Vilar-Gomez","year":"2015","unstructured":"Vilar-Gomez E, Martinez-Perez Y, Calzadilla-Bertot L, Torres-Gonzalez A, Gra-Oramas B, Gonzalez-Fabian L, et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology. 2015;149:367\u201378.e5.","journal-title":"Gastroenterology."},{"key":"686_CR48","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1111\/ijcp.12384","volume":"68","author":"JPH Wilding","year":"2014","unstructured":"Wilding JPH. The importance of weight management in type 2 diabetes mellitus. Int J Clin Pract. 2014;68:682\u201391.","journal-title":"Int J Clin Pract."},{"key":"686_CR49","doi-asserted-by":"crossref","first-page":"106651","DOI":"10.1016\/j.vascn.2019.106651","volume":"101","author":"VS Jensen","year":"2020","unstructured":"Jensen VS, Tveden-Nyborg P, Zacho-Rasmussen C, Quaade ML, Ipsen DH, Hvid H, et al. Variation in diagnostic NAFLD\/NASH read-outs in paired liver samples from rodent models. J Pharmacol Toxicol Methods. 2020;101:106651.","journal-title":"J Pharmacol Toxicol Methods."},{"key":"686_CR50","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/j.jhep.2018.05.002","volume":"69","author":"RE Castro","year":"2018","unstructured":"Castro RE, Diehl AM. Towards a definite mouse model of NAFLD. J Hepatol. 2018;69:272\u20134.","journal-title":"J Hepatol."},{"key":"686_CR51","doi-asserted-by":"crossref","first-page":"4904","DOI":"10.3748\/wjg.v25.i33.4904","volume":"25","author":"ML Boland","year":"2019","unstructured":"Boland ML, Or\u00f3 D, T\u00f8lb\u00f8l KS, Thrane ST, Nielsen JC, Cohen TS, et al. Towards a standard diet-induced and biopsy-confirmed mouse model of non-alcoholic steatohepatitis: Impact of dietary fat source. World J Gastroenterol. 2019;25:4904\u201320.","journal-title":"World J Gastroenterol."}],"container-title":["International Journal of Obesity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41366-020-00686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-020-00686-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41366-020-00686-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,9,16]],"date-time":"2021-09-16T23:10:19Z","timestamp":1631833819000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41366-020-00686-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,17]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["686"],"URL":"https:\/\/doi.org\/10.1038\/s41366-020-00686-1","relation":{},"ISSN":["0307-0565","1476-5497"],"issn-type":[{"value":"0307-0565","type":"print"},{"value":"1476-5497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,17]]},"assertion":[{"value":"11 March 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 August 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 September 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"All authors are current\/former employees of Glaceum Inc. and hold stocks\/shares. Glaceum Inc. provided funding for the research, and holds Patent US9783551B2, which grants intellectual properties (IP) for the synthesis and use of the compounds in the article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}